Obesity and insulin resistance are an escalating health problem in Australian adolescents. Unmanaged, they are likely to progress to type 2 diabetes and early atherosclerosis and which may pose a major burden on health care resources. However, treatment strategies are currently limited because of the lack of evidence. This PhD research aims to identify, summarise and test an effective and evidence-based approach of dietary management for overweight/obese adolescents and older children with clini ....Obesity and insulin resistance are an escalating health problem in Australian adolescents. Unmanaged, they are likely to progress to type 2 diabetes and early atherosclerosis and which may pose a major burden on health care resources. However, treatment strategies are currently limited because of the lack of evidence. This PhD research aims to identify, summarise and test an effective and evidence-based approach of dietary management for overweight/obese adolescents and older children with clinical insulin resistance or prediabetes.Read moreRead less
Bisphosphonate Therapy With Zoledronate Or Tenofovir Switching To Improve Low Bone Mineral Density In HIV-Infected Adults: A Strategic, Randomised Trial
Funder
National Health and Medical Research Council
Funding Amount
$716,300.00
Summary
Most HIV+ Australians receive tenofovir, a ‘preferred’ drug in all HIV treatment guidelines, and may do for decades, as HIV therapy is lifelong and because there are very few new HIV drugs. 40% of HIV+ adults have low bone density and HIV+ adults experience more fractures. Of all HIV drugs, tenofovir causes the most bone loss. This trial compares two approaches: a drug to improve bone density and switching tenofovir to another drug. This ‘treat versus switch’ approach is a world-first for HIV.
Fenofibrate And Microvascular Events In Type 1 Diabetes (FAME 1) Trial
Funder
National Health and Medical Research Council
Funding Amount
$2,883,529.00
Summary
Diabetes is one of the commonest cause of blindness in adults. Vision loss, which is irreversible, is a most feared complication of diabetes. A blood fat lowering drug called fenofibrate, available in Australia, has been shown to reduce eye damage in people with Type 2 diabetes by 35-40%, and to prevent eye damage in Type 1 diabetic animal models. This study will evaluate the potential benefits of fenofibrate in 450 adults with Type 1 diabetes who have early diabetic eye damage.
Cystic Fibrosis - Insulin Deficiency, Early Action (CF-IDEA)
Funder
National Health and Medical Research Council
Funding Amount
$185,485.00
Summary
Cystic Fibrosis (CF) is the most common life-threatening genetic condition affecting Australian children. As well as repeated lung infections, children with CF develop insulin deficiency and eventually diabetes. The CF-IDEA trial (Cystic Fibrosis – Insulin Deficiency, Early Action) will determine whether starting insulin treatment before the onset of diabetes (earlier than current practice) will improve the health of children with CF by improving body weight and lung function.
The overall aim is to improve treatments and outcomes for people with osteoporosis. This will be achieved by better predicting those who are likely to fracture and subsequently those who do well post fracture from those who do poorly. Following an osteoporotic fracture there is an increased risk of re- fracture and of premature death. This research will define those risk factors for fracture, re-fracture and early death in a large group of men and women followed for over 20 years.
Defining the molecular and cellular mechanisms of beta cell dysfunction. This project will investigate the influence of environment in the functional adaptation and maladaptation of pancreatic beta cells in diabetes. The research will define the molecular and cellular mechanisms linking environmental triggers such as obesity, high fatty acid levels and hyperglycaemia to beta cell dedifferentiation and dysfunction.